BackgroundNew-generation antiepileptic drugs (AEDs) tend to replace traditional AEDs as the first-line choice for epilepsy. However, whether this change results in better outcome, especially in China, remains unknown.Methodology/Principal FindingsTwo broad spectrum AEDs, the traditional drug of sustained-release formulation of valproate (SRVPA) and the new-generation drug of topiramate, were compared in patients with epilepsy as monotherapy in this multi-centre, observational cohort study from 2000 to 2011. The primary outcome was time to treatment failure. The secondary outcomes included time to first seizure, time to 12-month remission, and time to 24-month remission. Drug tolerability was assessed. Cox proportional hazard models (95% confidence interval [CI]) were used to analyse the relative risks expressed as hazard ratios (HR).Of the 1008 recruited patients, 519 received SRVPA and 489 received topiramate. SRVPA was better than topiramate (28.3% vs. 41.5%; HR = 0.62, [95% CI 0.49–0.77]; p<0.0001) in primary outcome, and in time to first seizure (56.1% vs. 69.3%; HR = 0.73, [95% CI 0.62–0.86]; p = 0.0002). No significant difference was observed between two groups in time to 12-month remission (52.6% vs. 42.5%; HR = 1.01, [95% CI 0.84–1.23]; p = 0.88) and time to 24-month remission (34.7% vs. 25.2%; HR = 1.11, [95% CI 0.88–1.42]; p = 0.38). 36 patients (6.9%) in SRVPA group and 37 patients (7.6%) in topiramate group presented treatment failure associated with intolerable adverse events, there was no significant difference between the two groups (p = 0.70).ConclusionsThe SRVPA is more suitable than topiramate for Chinese epileptic patients, and our results support the viewpoint that traditional AEDs should be the first-line choice for epilepsy rather than new-generation AEDs.
Diazepam (0.1-0.3 mg/kg) was injected intravenously, its effect on scalp EEG was evaluated visually and by computer in 84 cases of epilepsy, and long-term follow-up was carried out in an attempt to explore relationships between the EEG changes produced by diazepam and the prognosis in these patients. The average length of follow-up was 3 years (range 2-3.5) in 48 out of 84 cases (57%). The EEG visually responded to diazepam (abolition of abnormal activity with emergence of fast activity) in 33/48 cases. Subsequent follow-up showed that 29 (88%) of these had a good prognosis (seizure-free or a 50% or more reduction in seizures) and 4 others (12%) had a poor result (frequency of seizures increased, unchanged or decreased less than 50%). Fifteen patients had a negative EEG response to the drug, 4 (27%) of whom had a favorable outcome and 11 (73%) an unfavorable result. These results were statistically significant. The percentage of diazepam-induced EEG changes in beta activity (PDICB) was also significantly positively related to the percentage of reduction in seizure frequency in these patients (r = 0.55, p < 0.001). In 79% of patients with PDICB values more than 2, and 30% of those with values less than 2, a good outcome occurred whereas 21% and 70%, respectively, had a poor outcome (p < 0.001). These results showed that the patterns of EEG change induced by diazepam are intimately related to the outcome of epilepsy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.